Experimental evaluation of the specific activity of the new Angiolin dosage form in the research corneal burn's condition
DOI:
https://doi.org/10.14739/2310-1210.2019.6.186626Keywords:
(S)-2, 6-diaminohexanoic acid 3-methyl-1, 2, 4-triazolyl-5-thioacetate, thiotriazolineAbstract
Visual organ injuries are still one of the main causes of blindness and occupational disability. Despite the good protection of the eyeball by the bone walls of the orbit and adnexa oculi, its injuries are 5–10 % of the total number of all damages in peacetime and about 20 % in wartime.
Employees of the Department of Pharmaceutical Chemistry of Zaporizhzhia State Medical University (ZSMU) together with the specialists of the SPA “Farmatron” under the supervision of professor I. A. Mazur synthesized a new compound, called Angiolin.
The aim of the research is to study the anti-inflammatory, wound-healing, reparative activity of the Angiolin eye drops action during a chemical burn of the cornea rabbits modeling.
Materials and methods: The pharmacological efficacy of the prepared Angiolin eye drops in concentrations: 0.5 %, 1.0 %, 1.5 %, 2.0 % and 2.5 % has been studied. All studies were carried out on 40 eyes of 20 Chinchilla breed rabbits of both sexes weighing 2.1–3.5 kg. The chemical burn model was reproduced according to the Obenberger method using 10 % sodium hydroxide solution (application of8 mm blotting paper), exposure time 20 seconds, after preliminary installation anesthesia with 0.5 % Alcaine solution.
Results. Based on experimental data, it can be noted that Angiolin eye drops in concentrations: 1.0 %, 1.5 %, 2.0 %, 2.5 % show almost the same pharmacological activity, and 1 % Angiolin eye drops were the most effective, that gives us the opportunity for further study.
Conclusions. Angiolin eye drops exhibit high anti-inflammatory, wound healing, reparative activity in the treatment of eye burn. As a result of the study, it was found that 1 % of Angiolin eye drops turned out to be the most effective. The obtained results are an experimental rationale for further study of 1 % Angiolin eye drops.
References
Belenichev, I. F., Mazur, I. A., Kucherenko, L. I., Nagornaya, E. A., Gorbacheva, S. V., & Bidnenko, A. S. (2016). The molecular and ultrastructural aspects of the formation of mitochondrial dysfunction in the modeling of chronic cerebral ischemia: The mitoprotective effects of Angiolin. Neurochemical Journal, 10(2), 131-136. doi: 10.1134/s1819712416010025
Kucherenko, L. I., Hromyleva, O. V., Mazur, I. A., & Shishkina, S. V. (2017). Theoretical study about L-arginine complexes formation with thiotriazolin. Zaporozhye medical journal, 19(1), 108-112. doi: 10.14739/2310-1210.2017.1.91736
Chekman, I. S., Kazakova, O. О., Mazur, I. A., Nahorna, О. О., Bielenichev, I. F., & Horchakova, N. O. et al. (2017). Novyi oryhіnalnyi metabolіtotropnyi endotelіoprotektor “Angіolіn”: kvantovo-khіmіchnі parametry ta osoblyvostі farmakolohіchnoi dіi [New original metabolitotropic endothelioprotector "Angiolin": quantum-chemical parameters and peculiarities of pharmacological action]. Reports Of The National Academy Of Sciences Of Ukraine, 8, 86-93. doi: 10.15407/dopovidi2017.08.086 [in Ukrainian]
Kolesnik, Yu. M., Chekman, I. S., Mazur, I. A., Bielenichev, I. F., Horchakova, N. A. & Nahorna, О. О. (2014). Mekhanizmy rozvytku endotelialnoi dysfunktsii ta poshuk endotelioprotektoriv [Mechanisms of development of endothelial dysfunction and search for endothelioprotectors]. Journal of the National academy of medical sciences of Ukraine, 20(3), 289-299. [in Ukrainian].
Gladunova, E. P., Shirolapova, A. Ju., & Kurkin, V. A. (2015). Sovershenstvovanie obespechenija naselenija kontroliruemymi gruppami lekarstvennyh preparatov [Improving the provision of the population with controlled drug groups]. Pharmacy, 2, 32-36. [in Russian].
Mashkovskij, M. D. (2012). Lekarstvennye sredstva [Drugs]. (16th ed.) Moscow. [in Russian].
Chekman, I. S., Nebesna, T. Yu., Kazakova, O. O., & Simonov, P. V. (2010). Farmakofory: stvorennia likarskykh zasobiv [Pharmacophores: the creation of medicines]. Journal of the Academy of Medical Sciences of Ukraine, 16(3), 424-437.[in Ukrainian].
Kucherenko, L. I., Belenichev, I. F. & Bidnenko, A. S., (2015). Angiolin – novyj predstavitel metabolitotropnyh preparatov s vyrazhennym vlijaniem na jendotelij sosudov golovnogo mozga i serdca [Angiolin – is an ewrepresentative of metabolitotropic drugs with pronounced effect on the vascular endothelium of the brain and heart]. МНО Inter-Medical, 4(10), 11-14. [in Russian].
Bidnenko, O. S. (2014). Shchodo tekhnolohii vyrobnytstva substantsii “Lizynii” [As for the technology of production of the substance “Lysine”]. Modern aspects of medicine and pharmacy. Proceedings of the Scientific and Practical Conference, (p. 163). Zaporizhzhia. [in Ukrainian].
Khurana, A. K., Khurana, Aruj K. & Khurana, B. (Eds.). (2015). Review of Ophthalmology. (6th ed.). India: Jaypee Brothers Medical Publishers (Verlag).
Khurana, A. K., Khurana, Aruj K. &Khurana, B. (Eds.). (2015). Comprehensive Ophthalmology.(6th ed.). New Delhi: Jaypee Brothers Medical Publishers (Verlag).
Purdy, E. P. (Ed.). (2012). Basic and Clinical Science Course. Section 1: Update on General Medicine. Canada: American Academy of Ophthalmology.
Chalam, K. V. (Ed.). (2012). Basic and Clinical Science Course. Section 2: Fundamentals and Principles of Ophthalmology. Canada: American Academy of Ophthalmology.
Raab, E. L. (Ed.). (2012). Basic and Clinical Science Course. Section 6: Pediatric Ophthalmology and Strabismus. Canada: American Academy of Ophthalmology.
Holds, J. B. (Ed.). (2012). Basic and Clinical Science Course. Section 7: Orbit, Eyelids, and Lacrimal System. Canada: American Academy of Ophthalmology
Downloads
How to Cite
Issue
Section
License
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access)